Search

Your search keyword '"Guarneri L"' showing total 166 results

Search Constraints

Start Over You searched for: Author "Guarneri L" Remove constraint Author: "Guarneri L"
166 results on '"Guarneri L"'

Search Results

1. Metavalent bonding in crystalline solids: how does it collapse?

2. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

3. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

4. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study

5. Efficacy and safety of pangenotypic DAAs for chronic HCV infection: real-world data from the RESIST-HCV cohort

6. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

9. Epidemiologia delle farmacoresistenze di HIV nella regione Sicilia

10. Second-generation DAAs for HCV: real-life efficacy in the RESIST-HCV cohort

11. PC.01.10 LIVER AND CARDIOVASCULAR MORTALITY AFTER DAAS: DATA FROM THE RESIST-HCV COHORT

14. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

15. Disease outcomes after DAA-induced SVR: data from the resist-HCV cohort

17. Efficacy of oral direct acting antivirals for treatment of advanced chronic hepatitis or compensated cirrhosis due to hepatitis C virus infection: The real-life experience of the Sicily registry

18. Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs)

19. Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs)

20. Non-invasive tools to ruling out large varices: RESIST-HCV vs Baveno VI criteria in a large cohort of patients with HCV cirrhosis

21. Efficacy and safety of 12-week DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort

22. Occurrence of hepatocellular carcinoma in patients with hepatitis C virus related liver disease treated with direct-acting antivirals

23. Efficacy of oral Direct Acting Antivirals for the treatment of chronic hepatitis/cirhhosis due to hepatitis C virus infection: the real-life experience of the Sicily Registry

24. Risk of hepatocellular carcinoma recurrence in hepatitis C cirrhotic patients treated with direct acting antivirals

25. Treatment of elderly HCV patients with severe fibrosis: safety and efficacy data from RESIST-HCV, a large regional database

26. PS-149 - Disease outcomes after DAA-induced SVR: data from the resist-HCV cohort

27. Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort

30. Test for CCR5 tropism and treatment with maraviroc in Sicily: an observational retrospective multicentre study

49. Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery.

50. Mouse antithrombotic assay: the effects of Ca++ channel blockers are platelet-independent.

Catalog

Books, media, physical & digital resources